2.4 Study treatment
In this study, patients were treated with HDM SLIT-tablet (ACARIZAX®; 12-SQ-HDM sublingual lyophilizate immunotherapy ALK-Abelló A/S, Hørsholm, Denmark). HDM SLIT-tablet is approved for the treatment of HDM induced AR by the Dutch authorities since July 2016 and reimbursed as of October 2017. HDM SLIT-tablet is a lyophilisate containing standardized allergen extract from two house-dust-mite species, D. pteronyssinus and D. farinae. The first dose was self-administered under medical supervision, and subjects were monitored for 30 minutes after first intake. Subsequent doses were self-administered at home. The tablet was to be placed under the tongue and allowed to remain there until dissolved. Subjects were advised not to swallow during the first minute after administration, food and beverage was not allowed for 5 minutes thereafter. The study duration was one year.